Trial Profile
Pulse Reduction On Beta-blocker and Ivabradine Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Dilated cardiomyopathy; Heart failure
- Focus Therapeutic Use
- Acronyms PROBE-IT
- 19 Dec 2023 Status changed from active, no longer recruiting to completed.
- 13 Nov 2023 Results (n=22) hypothesizing that failure to adequately reduce heart rate (HR) contributes to non-response to beta-blockerspresented at the American Heart Association Scientific Sessions 2023
- 31 Oct 2022 Planned End Date changed from 1 Jun 2022 to 30 Jun 2023.